《新股》百圖生科BioMap據報擬於一年半內來港上市
彭博社報道,百圖生科(BioMap)CEO劉維指,計劃一年半內尋求在香港公開上市;他又指,香港對處於創業早期階段的科技公司而言是上市首選地。
報道指,公司由百度創始人李彥宏與原百度風投CEO劉維在2020年創立。BioMap與製藥公司、生物技術公司和學術研究人員合作,將AI應用於藥物研究,迄今已開發出50多種早期候選藥物。
港投公司去年6月公布,與BioMap簽訂策略合作協議,將為公司後續在港發展提供全方位的資源配對和支持,推動香港發展成為國際生物計算港。BioMap將推出加速器計劃「BioMap BioX」,預計未來5年在香港利用其大模型平台支持50個以上的前沿生命科學早期研發項目。(ss/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.